68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.

Inclusion Criteria:

1. Age ≥18 years old;

2. Cohort 1: Patients with suspected or confirmed myelofibrosis; Cohort 2: Patientswith primary/secondary myelofibrosis who were not treated with ruxolitinib.

3. The expected survival time is over 3 months

4. Voluntarily sign informed consent.

5. Willing and able to follow the research protocol;

6. The subject must be able to lie on the scanning bed for 20 minutes;

Exclusion Criteria:

1. Known allergic history to 68Ga FAPI or its excipients;

2. Patients who can not tolerate intravenous drug administration (such as needlefainting and blood fainting history);

3. Those who are not suitable for or unable to complete imaging tests such as PET dueto special reasons, including claustrophobia and radiophobia;

4. pregnant and lactating women;

5. Workers who are exposed to radiation for a long period of time;

6. Serious diseases of the heart, kidney, lung, blood vessel, nervous system, mentalsystem, immune deficiency diseases and hepatitis/cirrhosis;

7. Participating in other interventional clinical trials within 1 month beforescreening;

8. Patients undergoing chemotherapy, immunotherapy or molecular targeted therapy due toother cancers;

9. There are other circumstances that the researcher thinks are not suitable forparticipating in this study;